Results 91 to 100 of about 62,912 (312)

Tofacitinib Ameliorates Lupus Through Suppression of T Cell Activation Mediated by TGF-Beta Type I Receptor

Frontiers in Immunology, 2021
Autoreactive T cells play a crucial role in the pathogenesis of systemic lupus erythematosus (SLE). TGF-β type I receptor (TGFβRI) is pivotal in determining T cell activation.
Qing Yan, Qing Yan, Weiwei Chen, Weiwei Chen, Hua Song, Xianming Long, Zhuoya Zhang, Xiaojun Tang, Hongwei Chen, He Lin, Lingyun Sun, Lingyun Sun   +11 more
doaj   +1 more source

Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives. [PDF]

, 2019
Tofacitinib is an oral Janus kinase inhibitor approved for the treatment of psoriatic arthritis (PsA). It provides an alternative option for patients who have had an inadequate response and tolerance to other disease modifying antirheumatic drugs (DMARDs)
Beck, Kristen M, Liao, Wilson, Ly, Karen, Orbai, Ana-Maria, Smith, Mary P   +4 more
core  

Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study

Annals of the Rheumatic Diseases
Objectives We report the safety, tolerability and efficacy of tofacitinib in patients with juvenile idiopathic arthritis (JIA) in an ongoing long-term extension (LTE) study. Methods Patients (2–
H. Brunner, J. Akikusa, E. Al-Abadi, J. Bohnsack, A. Boteanu, G. Chédeville, R. Cuttica, Wendy De La Pena, Lawrence Jung, Ozgur Kasapcopur, K. Kobusińska, G. Schulert, C. Neiva, R. Rivas-Chacon, Juan Cruz Rizo Rodriguez, M. Vázquez-del Mercado, L. Wagner-Weiner, J. Weiss, Carine Wouters, Holly B Posner, A. Wouters, Cheng Chang, Claire White, K. Kanik, Shixue Liu, Alberto Martini, D. Lovell, N. Ruperto   +27 more
semanticscholar   +1 more source

Successful experience of tofacitinib treatment in patients with Fibrodysplasia Ossificans Progressiva

Pediatric Rheumatology Online Journal, 2023
Aim of Study To assess the safety and efficacy of tofacitinib in patients with FOP refractory to standard of care treatment. Material and Methods In the retrospective observation study we included information about 13 genetically confirmed FOP patients ...
I. Nikishina, S. Arsenyeva, V. Matkava, A. Arefieva, M. I. Kaleda, A. Smirnov, L. M. Blank, M. Kostik   +7 more
semanticscholar   +1 more source

Association of Abatacept With Lower Mortality Risk Compared to Rituximab in Rheumatoid Arthritis–Associated Interstitial Lung Disease: An Emulated Target Trial

Arthritis &Rheumatology, EarlyView.
Objective The optimal treatment strategy for rheumatoid arthritis–associated interstitial lung disease (RA‐ILD) remains uncertain, and direct comparative data between biologics are limited. This study aimed to evaluate the effectiveness and safety of abatacept compared with rituximab in patients with RA‐ILD.
Po‐Cheng Shih, Shiow‐Ing Wang, Qing‐Wen Wang, James Cheng Chung Wei   +3 more
wiley   +1 more source

Integrated safety analysis of tofacitinib from Phase 2 and 3 trials of patients with ankylosing spondylitis

Advances in Rheumatology
Objectives Describe tofacitinib safety from an integrated analysis of randomized controlled trials (RCTs) in patients with ankylosing spondylitis (AS). Method Pooled data from Phase 2 (NCT01786668; 04/2013–03/2015)/Phase 3 (NCT03502616; 06/2018–08/2020 ...
Atul Deodhar, Servet Akar, Jeffrey R. Curtis, Bassel El-Zorkany, Marina Magrey, Cunshan Wang, Joseph Wu, Solomon B. Makgoeng, Ivana Vranic, Sujatha Menon, Dona L. Fleishaker, Annette M. Diehl, Lara Fallon, Arne Yndestad, Robert B. M. Landewé   +14 more
doaj   +1 more source

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis. [PDF]

, 2015
ObjectiveTofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). The pathways affected by tofacitinib and the effects on gene expression in situ are unknown.
Boyle, DL, Bradley, J, Firestein, GS, Hodge, J, Kaplan, I, Kavanaugh, A, Krishnaswami, S, Luo, Z, Mandel, D, Mease, P, Rosengren, S, Shurmur, R, Singhal, AK, Soma, K, Wei, N   +14 more
core  

Patterns of Tumor Necrosis Factor Inhibitor (TNFi) Biosimilar Use Across United States Rheumatology Practices. [PDF]

, 2020
ObjectiveIt is unclear if biosimilars of biologics for inflammatory arthritis are realizing their promise to increase competition and improve accessibility.
Bansback, Nick, Curtis, Jeffrey R, Evans, Michael, He, Zeling, Huang, Jie, Johansson, Tracy, Liao, Katherine P, Michaud, Kaleb, Schmajuk, Gabriela   +8 more
core   +1 more source

Effectiveness of Tofacitinib in Pre-adolescent Alopecia Areata: A Retrospective Case Series and Literature Review

Acta Dermato-Venereologica, 2023
Alopecia areata (AA) is a common cause of hair loss in children. Despite numerous therapeutic options for paediatric AA, none have been found to be both effective and safe. Recent studies have demonstrated the efficacy and safety of the Janus kinase (JAK)
Jundong Huang, Tingting Li, Zixin Tan, Yan Tang, Ji Li, Fangfen Liu, W. Shi   +6 more
semanticscholar   +1 more source

P336 Association between the prior duration of remission and efficacy outcomes in patients with Ulcerative Colitis treated with tofacitinib 10 mg twice daily who were in stable remission and either dose-reduced to tofacitinib 5 mg twice daily or remained on 10 mg twice daily: 6-month data from the double-blind, randomised RIVETING study [PDF]

, 2021
Marla C. Dubinsky, Geert D’Haens, William J. Sandborn, Siew C. Ng, Julián Panés, Chinyu Su, Nervin Lawendy, Irina Lazariciu, Sean Gardiner, Rajiv Mundayat, Nicole Kulisek, Irene Modesto, Joana Torres   +12 more
openalex   +1 more source